FibroMAX: towards a new universal biomarker of liver disease?

Expert review of molecular diagnostics

Morra R, Munteanu M, Imbert-Bismut F, Messous D, Ratziu V, Poynard T

2007 Expert Rev. Mol. Diagn. Volume 7 Issue 5

PubMed 17892356 DOI 10.1586/14737159.7.5.481

FibroTest ActiTest SteatoTest NashTest AshTest Reliability False Positive/Negative vs. Biopsy vs. Elastography vs. Biomarkers HCV HBV HIV co-infected Metabolic Diseases Alcohol Other liver Disease Fibrosis Cirrhosis Steatosis Activity/Inflammation Portal Hypertension Diabetes OverWeight HyperLipidemia

Among the noninvasive alternatives to liver biopsy, several studies have demonstrated the predictive value and a better benefit-to-risk ratio than biopsy of five combinations of simple serum biochemical markers (the super combination being FibroMAX (BioPredictive, Paris, France) in patients at risk of chronic liver diseases: FibroTest (BioPredictive) for the quantitative assessment of fibrosis; SteatoTest (BioPredictive) for the quantitative assessment of steatosis; ActiTest (BioPredictive) for the quantitative assessment of necroinflammatory activity in chronic viral hepatitis C and B; NashTest (BioPredictive) for the categorical diagnosis of nonalcoholic steatohepatitis; and AshTest for the quantitative assessment of alcoholic steatohepatitis (also known in the USA as HCV-FibroSURE, HBV-FibroSURE, ASH-FibroSURE and NASH-FibroSURE; LabCorp, NC, USA). The possible causes of false-negative and false-positive results are also better identified. These tests, which are now available in 50 countries, can facilitate the screening and management of the most frequent liver diseases.

Citation Reference: